Oral cannabinoid formulations

Patent metadata

Field	Value
Publication number	US-11426362-B2
Application number	US-201816486750-A
Country	US
Kind code	B2
Filing date	Feb 15, 2018
Priority date	Feb 17, 2017
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).

First claim

The invention claimed is:

1. An oral formulation comprising:
(i) a plurality of micelles, wherein each micelle comprises a non-ionic surfactant and one or more cannabinoids, wherein the one or more cannabinoids are incorporated within the micelle; and
(ii) an aqueous solvent comprising water and an antioxidant that is soluble in the aqueous solvent;
wherein the micelles are miscible in the aqueous solvent.

2. The oral formulation of claim 1 , wherein the one or more cannabinoids, non-ionic surfactant and water comprise at least 80% by weight of the oral formulation.

3. The oral formulation of claim 1 , further comprising one or more of: a sweetener, a taste masking agent, a flavor, and a preservative.

4. The oral formulation of claim 1 , wherein the non-ionic surfactant is present in an amount sufficient to ensure dissolution of the one or more cannabinoids in the formulation.

5. The oral formulation of claim 1 , wherein the diameter of the micelles is in the nanometer range.

6. The oral formulation of claim 1 , wherein the one or more cannabinoids, non-ionic surfactant and water comprise, at least 85% by weight of the oral formulation.

7. The oral formulation of claim 1 , wherein the non-ionic surfactant is Polyoxyethylene (20) sorbitan monooleate, Polysorbate 80, macrogolglycerol hydroxystearate, or Polyoxamers.

8. The oral formulation of claim 7 , wherein the non-ionic surfactant is macrogolglycerol hydroxystearate.

9. The oral formulation of claim 8 , wherein the macrogolglycerol hydroxystearate is present in an amount of from 10 to 500 mg/mL.

10. The oral formulation of claim 1 , wherein the one or more cannabinoids comprise cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) or tetrahydrocannabivarinic acid (THCVA).

11. The oral formulation of claim 1 , wherein the one or more cannabinoids comprise CBD or CBDV.

12. The oral formulation of claim 10 , wherein the one or more cannabinoids is present in an amount of 0.5 to 50 mg/mL.

13. The oral formulation of claim 1 , wherein the non-ionic surfactant is present in an amount of from 10 to 500 mg/mL, and the cannabinoid is present in an amount of from 0.5 to 50 mg/mL.

14. The oral formulation of claim 1 , wherein the ratio of the one or more cannabinoids to the non-ionic surfactant ranges from 1:5 to 1:20.

15. The oral formulation of claim 14 , wherein the ratio of the one or more cannabinoids to the non-ionic surfactant ranges from 1:8 to 1:20.

16. The oral formulation of claim 14 , wherein the ratio of the one or more cannabinoids to the non-ionic surfactant ranges from 1:12 to 1:20.

17. The oral formulation of claim 1 , further comprising a taste masking agent.

18. The oral formulation of claim 1 , further comprising a flavoring.

19. The oral formulation of claim 1 , further comprising one or more preservatives.

20. The oral formulation of claim 1 , further comprising a sweetener.

21. The oral formulation of claim 1 , comprising one or more cannabinoids, macrogolglycerol hydroxystearate, glycerol, peppermint flavoring, methyl parahydroxybenzoate, propyl parahydroxybenzoate, ascorbic acid, and sucralose, wherein the one or more cannabinoids is CBD, CBDV, or both.

22. The oral formulation of claim 1 , which is stable in Climatic Zones I and II for up to 12 months at 30° C.

23. The oral formulation of claim 1 , wherein the aqueous solvent comprises a taste masking agent, a sweetener, or a combination thereof.

24. The oral formulation of claim 19 , wherein the preservative is methyl parahydroxybenzoate, propyl parahydroxybenzoate, or a combination thereof.

25. The oral formulation of claim 20 , wherein the sweetener is sucralose.

26. The oral formulation of claim 1 , wherein the antioxidant is ascorbic acid.

27. The oral formulation of claim 18 , wherein the flavoring is blackcurrant, orange, or peppermint oil.

28. The oral formulation of claim 27 , wherein the flavoring is peppermint oil.

29. The oral formulation of claim 23 , wherein the taste masking agent is glycerol.

30. The oral formulation of claim 1 , wherein the antioxidant is present in an amount ranging from 0.1 mg/mL to 15 mg/mL.

31. The oral formulation of claim 1 , wherein the antioxidant is present in an amount ranging from 1 mg/mL to 10 mg/mL.

32. A method of treating a condition requiring the administration of a neuroprotectant or anti-convulsive medication comprising administering the oral formulation of claim 1 .

33. A method of treating seizures comprising administering the oral formulation of claim 1 .

34. The method of claim 32 , wherein the condition is selected from the group consisting of Dravet syndrome, Lennox Gastaut syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's disease, and autism.

35. A method of preparing the oral formulation of claim 1 , comprising:
i) preparing a surfactant phase containing one or more cannabinoids and a non-ionic surfactant, optionally containing one or more excipients that dissolve in the surfactant phase;
ii) preparing an aqueous phase comprising water and an antioxidant, optionally containing one or more excipients that dissolve in the aqueous phase; and
iii) mixing the surfactant phase and the aqueous phase to form the oral formulation.

Assignees

• Gw Res Ltd

Inventors

• Wright Stephen
• Wilkhu Jitinder

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K47/44

  Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title